Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)

Sponsor
University Hospital, Bonn
Study ID
NCT02537054
Phase
PHASE2
Status
Completed

Conditions

  • Pseudoxanthoma Elasticum

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine whether Aflibercept (Eylea) is effective in the treatment of choroidal neovascularization and fibrovascular proliferation in patients with pseudoxanthoma elasticum (PXE) in terms of preservation or improvement of visual acuity.

Key Dates

Start date
Sep 30, 2015
Status verified
Apr 2019
Primary completion
Jul 2, 2018
Completion
Jul 2, 2018

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Aflibercept
    2 mg/ dose (pro re nata, maximum 1 dose/ month), intravitreal use

Primary Outcome Measure

Change in distance best corrected visual acuity between end-of study visit and screening visit [ Time Frame: Screening visit (day -28 - 0) and end-of-study visit (day 360 +/- 7) ]

Related Studies